NeoGenomics Inc (NEO) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Total Assets Chart for NeoGenomics Inc
NeoGenomics Inc (NEO) total assets for FY2025 were USD 1.4B, a -17.0% change from FY2024. NeoGenomics Inc's total assets grew from USD 186.00 in 2000 to USD 1.4B in 2025 (731091297.8% over 25 years). Total assets compound annual growth rate: 5-year CAGR of 6.6%, 10-year CAGR of 14.0%, 20-year CAGR of 42.9%.
Total Assets (US Dollars)
R&D as % of Revenue
Key Stats
- Market Cap
- $2.14B
- Implied Share Price
- $16.65
- Enterprise Value
- $2.66B
- Revenue (TTM)
- $766.29M
- EBITDA
- $24.32M
- Profit Margin
- -6.77%
- Trailing P/E
- —
- Forward P/E
- 222.22
- Price/Book (MRQ)
- 3.00
- Price/Sales (TTM)
- 2.83
- EV/EBITDA
- 197.32
- EV/Revenue
- 3.47
- Dividend Yield
- —
- Book Value
- $6.14
- Free Cash Flow (FY2025)
- -$21.78M
- Free Cash Flow Yield
- -1.02%
Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.